Aprea Therapeutics, Inc. (APRE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aprea Therapeutics, Inc. (APRE) closed at USD 0.58 on 2026-10-14, a change of -58.9 % over the past year, with a market capitalization of USD 7.78M.

Aprea Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aprea Therapeutics, Inc. key figures

Previous close

USD 0.58 (2026-10-14)

1-year change

-58.9 %

Market cap

USD 7.78M

Enterprise value

USD -32.73M

P/E ratio (trailing)

-0.65

P/E ratio (forward)

-1.82

EPS (trailing)

-0.95

EPS (forward)

-0.34

PEG ratio

n/a

Price to book

0.20

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.45

Employees

8

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aprea Therapeutics, Inc. and compare it with other stocks.